HedgeChatter

  • Home /
  • Tag Archives

ITMN

7:07 am InterMune reports Phase 3 ASCEND trial results of pirfenidone in idiopathic pulmonary fibrosis; study meets primary and both key secondary endpoints

moreView todays social media effects on ITMNView the latest stocks trending across Twitter. Click to view dashboardSee who InterMune is hiring next, click here to view […]

February 25, 2014 Bystocknews , Comments Off on 7:07 am InterMune reports Phase 3 ASCEND trial results of pirfenidone in idiopathic pulmonary fibrosis; study meets primary and both key secondary endpoints read more

InterMune’s lung drug delays disease progression in trial

[Reuters] – InterMune Inc said its experimental lung drug reduced the progression of a disease that leads to loss of lung function in a late-stage trial. The trial compared the drug, pirfenidone, with a placebo, and showed that after 52 weeks of treatmen moreView todays social media effects on ITMNView the latest stocks trending across Twitter. Click to view dashboardSee […]

February 25, 2014 Bystocknews , Comments Off on InterMune’s lung drug delays disease progression in trial read more

InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF)

[PR Newswire] – BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ — InterMune, Inc. (ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), demonstrated that pirfenid moreView todays social media effects on ITMNView the latest stocks trending across Twitter. Click to view dashboardSee who InterMune is hiring next, click here […]

February 25, 2014 Bystocknews , Comments Off on InterMune Reports Phase 3 ASCEND Trial Results of Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF) read more

INTERMUNE INC Files SEC form 10-K, Annual Report

moreView todays social media effects on ITMNView the latest stocks trending across Twitter. Click to view dashboardSee who InterMune is hiring next, click here to view […]

February 24, 2014 Bystocknews , Comments Off on INTERMUNE INC Files SEC form 10-K, Annual Report read more

InterMune Is Set To Outperform Its Main Competitor

moreView todays social media effects on ITMNView the latest stocks trending across Twitter. Click to view dashboardSee who InterMune is hiring next, click here to view […]

February 12, 2014 Bystocknews , Comments Off on InterMune Is Set To Outperform Its Main Competitor read more

PropThink: Esbriet Sales Demonstrating Growth; Expansion into New Markets Continues

[ACN Newswire] – By Jake KingEsbriet (perfenidone) sales in Europe have begun to pick up according to InterMune’s (NASDAQ:ITMN) third quarter results , driven largely (91%) by sales in Germany where the drug received government … moreView todays social media effects on ITMNView the latest stocks trending across Twitter. Click to view dashboard […]

November 9, 2012 Bystocknews , Comments Off on PropThink: Esbriet Sales Demonstrating Growth; Expansion into New Markets Continues read more